文献速递重症综合管理与镇静镇痛心脑血管急症

重症社区获得性肺炎链球菌脑膜炎:重症监护病房的临床与预后图景

Severe community-acquired Streptococcus pneumoniae bacterial meningitis: clinical and prognostic picture from the intensive care unit.
PubMed 文献 · Crit Care · 2023-02-23
一句话结论在16个西班牙ICU的255例重症肺炎链球菌脑膜炎患者中,30天死亡率为13.7%,抗生素治疗延迟启动是唯一可干预的死亡相关因素(OR 18.69)。

该回顾性、观察性、多中心队列研究纳入16个西班牙ICU收治的255例肺炎链球菌脑膜炎患者,评估其流行病学、治疗与结局。脑脊液培养阳性率89.7%,25.7%对青霉素不敏感,5.2%对头孢曲松或头孢噻肟不敏感;最常用经验性抗生素为第三代头孢菌素(47.5%)联合万古霉素(27.8%)或利奈唑胺(12.9%),88.6%患者接受激素治疗。抗生素治疗72小时后65.8%患者获得临床应答;30天死亡率为13.7%。多因素分析显示,抗生素启动延迟(OR 18.69;95%CI 2.13-163.97,p=0.008)、SOFA评分(OR 1.36;95%CI 1.12-1.66,p=0.002)和早期治疗失败(OR 21.75;95%CI 3.40-139.18,p=0.001)与30天死亡率独立相关,其中抗生素延迟启动是唯一可干预因素。

要点

  • 在255例重症肺炎链球菌脑膜炎患者中,30天死亡率为13.7%,低于既往报道。
  • 抗生素启动延迟与30天死亡率独立相关(OR 18.69;95%CI 2.13-163.97,p=0.008),是唯一可干预因素。
  • 早期治疗失败与30天死亡率独立相关(OR 21.75;95%CI 3.40-139.18,p=0.001)。
  • SOFA评分与30天死亡率独立相关(OR 1.36;95%CI 1.12-1.66,p=0.002)。
  • 抗生素治疗72小时后,65.8%患者获得临床应答;侵袭性机械通气(OR 10.74;95%CI 3.04-37.95,p<0.001)和感染性休克(OR 1.18;95%CI 1.03-1.36,p=0.017)与早期治疗失败相关。

适用人群与场景

  • 16个西班牙ICU收治的肺炎链球菌脑膜炎患者,共255例。

处置流程与药物剂量

  • 最常用经验性抗生素方案为第三代头孢菌素(47.5%),联合万古霉素(27.8%)或利奈唑胺(12.9%)。
  • 88.6%的患者接受了激素治疗方案。
  • 抗生素治疗启动后72小时评估临床应答。

研究设计与关键结果

  • 研究类型:回顾性、观察性、多中心队列研究;纳入16个西班牙ICU的255例肺炎链球菌脑膜炎患者。
  • 脑脊液培养阳性率为89.7%;25.7%的菌株对青霉素不敏感,5.2%对头孢曲松或头孢噻肟不敏感。
  • 抗生素治疗72小时后,65.8%的患者获得临床应答。
  • 多因素分析显示,侵袭性机械通气(OR 10.74;95%CI 3.04-37.95,p<0.001)和感染性休克(OR 1.18;95%CI 1.03-1.36,p=0.017)与早期治疗失败相关。
  • 30天死亡率为13.7%。
  • 多因素分析显示,与30天死亡率独立相关的因素包括:抗生素治疗启动延迟(OR 18.69;95%CI 2.13-163.97,p=0.008)、SOFA评分(OR 1.36;95%CI 1.12-1.66,p=0.002)和早期治疗失败(OR 21.75;95%CI 3.40-139.18,p=0.001)。
  • 124例患者(48.63%)出现神经系统并发症。

证据类型、等级与局限

  • 证据类型:回顾性、观察性、多中心队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,抗生素治疗延迟启动是唯一可干预的死亡相关因素,应关注ICU收治后尽早启动抗生素治疗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Severe community-acquired pneumococcal meningitis is a medical emergency. The aim of the present investigation was to evaluate the epidemiology, management and outcomes of this condition.

METHODS: This was a retrospective, observational and multicenter cohort study. Sixteen Spanish intensive care units (ICUs) were included. Demographic, clinical and microbiological variables from patients with Streptococcus pneumoniae meningitis admitted to ICU were evaluated. Clinical response was evaluated at 72 h after antibiotic treatment initiation, and meningitis complications, length of stay and 30-day mortality were also recorded.

RESULTS: In total, 255 patients were included. Cerebrospinal fluid (CSF) culture was positive in 89.7%; 25.7% were non-susceptible to penicillin, and 5.2% were non-susceptible to ceftriaxone or cefotaxime. The most frequent empiric antibiotic regimen was third-generation cephalosporin (47.5%) plus vancomycin (27.8%) or linezolid (12.9%). A steroid treatment regimen was administered to 88.6% of the patients. Clinical response was achieved in 65.8% of patients after 72 h of antibiotic treatment. Multivariate analysis identified two factors associated with early treatment failure: invasive mechanical ventilation (OR 10.74; 95% CI 3.04-37.95, p < 0.001) and septic shock (OR 1.18; 95% CI 1.03-1.36, p = 0.017). The 30-day mortality rate was 13.7%. Only three factors were independently associated with 30-day mortality: delay in start of antibiotic treatment (OR 18.69; 95% CI 2.13-163.97, p = 0.008), Sepsis-related Organ Failure Assessment (SOFA) score (OR 1.36; 95% CI 1.12-1.66, p = 0.002) and early treatment failure (OR 21.75 (3.40-139.18), p = 0.001). Neurological complications appeared in 124 patients (48.63%).

CONCLUSIONS: Mortality rate in critically ill patients with pneumococcal meningitis is lower than previously reported. Delay in antibiotic treatment following admission is the only amendable factor associated with mortality.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Martín-Cerezuela M, Aseginolaza-Lizarazu M, Boronat-García P, et al. Severe community-acquired Streptococcus pneumoniae bacterial meningitis: clinical and prognostic picture from the intensive care unit. Crit Care. 2023. PMID: 36823625. doi:10.1186/s13054-023-04347-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。